Sophie M. C. Gobeil

Sophie M. C. Gobeil

Auto-generated profile, based on publicly available information

Sophie M. C. Gobeil

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2020 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
RHRory Henderson
Rory Henderson
RERobert J. Edwards
Robert J. Edwards
KMKatayoun Mansouri
Katayoun Mansouri
KJKatarzyna Janowska
Katarzyna Janowska
VSVictoria Stalls
Victoria Stalls
PAPriyamvada Acharya
Priyamvada Acharya

6 August 2021 in Science
Verified
Journal Article
Open access
PDF file
SGSophie M.-C. Gobeil
Sophie M.-C. Gobeil
KJKatarzyna Janowska
Katarzyna Janowska
SMShana McDowell
Shana McDowell
KMKatayoun Mansouri
Katayoun Mansouri
RPRobert Parks
Robert Parks
PAPriyamvada Acharya
Priyamvada Acharya
SARS-CoV-2 from alpha to epsilon: As battles to contain the COVID-19 pandemic continue, attention is focused on emerging variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that have been deemed variants of concern because they are resistant to antibodies elicited by infection or vaccination or they increase transmissibility or disease severity. Three papers used functional and structural studies to explore how mutations in the viral spike protein affect its ability to infect host cells and to evade host immunity. Gobeil et al . looked at a variant spike protein involved in transmission between minks and humans, as well as the B1.1.7 (alpha), B.1.351 (beta), and P1 (gamma) spike variants; Cai et al . focused on the alpha and beta variants; and McCallum et al . discuss the properties of the spike protein from the B1.1.427/B.1.429 (epsilon) variant. Together, these papers show a balance among mutations that enhance stability, those that increase binding to the human receptor ACE2, and those that confer resistance to neutralizing antibodies. —VV

10 May 2021 in Nature
Verified
Journal Article
Closed access
PDF file
KSKevin O. Saunders
Kevin O. Saunders
ELEsther Lee
Esther Lee
RPRobert Parks
Robert Parks
DMDavid R. Martinez
David R. Martinez
DLDapeng Li
Dapeng Li
BHBarton F. Haynes
Barton F. Haynes

26 January 2022 in Science Translational Medicine
Verified
Journal Article
Open access
DMDavid R. Martinez
David R. Martinez
ASAlexandra Schaefer
Alexandra Schaefer
SGSophie Gobeil
Sophie Gobeil
DLDapeng Li
Dapeng Li
GCGabriela De la Cruz
Gabriela De la Cruz
RBRalph S. Baric
Ralph S. Baric
Severe acute respiratory syndrome coronaviruses 1 (SARS-CoV) and 2 (SARS-CoV-2), including SARS-CoV-2 variants of concern, can cause deadly infections. The mortality associated with sarbecovirus infection underscores the importance of developing broadly effective countermeasures against them, which could be key in the prevention and mitigation of current and future zoonotic events. Here, we demonstrate the neutralization of SARS-CoV; bat coronaviruses WIV-1 and RsSHC014; and SARS-CoV-2 variants D614G, B.1.1.7, B.1.351, P.1, B.1.429, B.1.526, B.1.617.1, and B.1.617.2 by a receptor binding domain (RBD)–specific human antibody, DH1047. Prophylactic and therapeutic treatment with DH1047 was protective against SARS-CoV, WIV-1, RsSHC014, and SARS-CoV-2 B.1.351 infection in mice. Binding and structural analysis showed high affinity binding of DH1047 to an epitope that is highly conserved among sarbecoviruses. Thus, DH1047 is a broadly protective antibody that can prevent infection and mitigate outbreaks caused by SARS-related strains and SARS-CoV-2 variants. Our results also suggest that the conserved RBD epitope bound by DH1047 is a rational target for a universal sarbecovirus vaccine.

19 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
Praveen JuvvadiPraveen Juvvadi
Praveen Juvvadi
DFDavid Fox
David Fox
BBBenjamin Bobay
Benjamin Bobay
MHMichael J. Hoy
Michael J. Hoy
SGSophie M. C. Gobeil
Sophie M. C. Gobeil
WSWilliam Steinbach
William Steinbach
Calcineurin is important for fungal virulence and a potential antifungal target, but compounds targeting calcineurin, such as FK506, are immunosuppressive. Here we report the crystal structures of calcineurin catalytic (CnA) and regulatory (CnB) subunits complexed with FK506 and the FK506-binding protein (FKBP12) from human fungal pathogens (Aspergillus fumigatus, Candida albicans, Cryptococcus neoformans and Coccidioides immitis). Fungal calcineurin complexes are similar to the mammalian complex, but comparison of fungal and human FKBP12 (hFKBP12) reveals conformational differences in the 40s and 80s loops. NMR analysis, molecular dynamic simulations, and mutations of the A. fumigatus CnA/CnB-FK506-FKBP12-complex identify a Phe88 residue, not conserved in hFKBP12, as critical for binding and inhibition of fungal calcineurin. These differences enable us to develop a less immunosuppressive FK506 analog, APX879, with an acetohydrazine substitution of the C22-carbonyl of FK506. APX879 exhibits reduced immunosuppressive activity and retains broad-spectrum antifungal activity and efficacy in a murine model of invasive fungal infection.

1 May 2021 in Cell
Verified
Journal Article
Closed access
WWWilton Bryan Williams
Wilton Bryan Williams
RMR. Ryan Meyerhoff
R. Ryan Meyerhoff
RER.J. Edwards
R.J. Edwards
HLHui Li
Hui Li
KMKartik Manne
Kartik Manne
BHBarton F. Haynes
Barton F. Haynes